ClinicalTrials.gg

Program

mecobalamin

Also written as “E0302 (mecobalamin)”, “Methylconalamin Injection(WP205)” and “Methylcobalamin Injection(WP205)”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Dementia · Peripheral Nervous System Diseases, led by 2 companies.

Furthest: phase 4, since Sep 12, 20058 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai60 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Wanbangde Pharmaceutical Group20 open or runningphase 1since Aug 27, 2025Aug 27, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2005First study: phase 4 study in Dementia With Vitamin B12 DeficiencyNew to EisaiEisai · NCT00165711 · China
  2. Mar 6, 20072 phase 3 studies in Amyotrophic Lateral SclerosisEisai · NCT00445172, NCT00444613
  3. Aug 26, 2010Phase 4 study in Peripheral Nervous System DiseasesEisai · NCT01192113 · 1,072 enrolled · China
  4. May 14, 2018Phase 3 study in Amyotrophic Lateral SclerosisEisai · NCT03548311 · 130 enrolled · Japan
  5. Mar 6, 2019Phase 1 study in Healthy SubjectsEisai · NCT03885882 · 24 enrolled · New Zealand
  6. Aug 27, 2025Wanbangde Pharmaceutical Group's first study: phase 1 study in Therapeutic Equivalency, HealthyNew to Wanbangde Pharmaceutical GroupWanbangde Pharmaceutical Group · NCT07158099 · 14 enrolled · China
  7. Nov 19, 2025Phase 1 study in Therapeutic Equivalency, HealthyWanbangde Pharmaceutical Group · NCT07281872 · 20 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07281872Therapeutic Equivalency, Healthy · China1CompletedWanbangde Pharmaceutical GroupNov 6, 202520
NCT07158099Therapeutic Equivalency, Healthy · China1CompletedWanbangde Pharmaceutical GroupSep 18, 202514
NCT03885882Healthy Subjects · New Zealand1CompletedEisaiJun 26, 201924
NCT03548311Amyotrophic Lateral Sclerosis · Japan3CompletedEisaiFeb 14, 2020130
NCT01192113Peripheral Nervous System Diseases · China4CompletedEisaiMay 20111,072
NCT00445172Amyotrophic Lateral Sclerosis · Japan3CompletedEisaiMar 31, 2017135
NCT00444613Amyotrophic Lateral Sclerosis · Japan3CompletedEisaiMar 2014373
NCT00165711Dementia With Vitamin B12 Deficiency · China4CompletedEisai

How it is read

Names in the registry

  • “E0302 (mecobalamin)”, 3 entries
  • “Methylconalamin Injection(WP205)”, 1 entry
  • “Methylcobalamin Injection(WP205)”, 1 entry
  • “Methylcobalamin for Injection”, 1 entry
  • “methylcobalamin”, 1 entry

Codes read as this program: WP205, E0302.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
mecobalamin (Eisai): development program | ClinicalTrials.gg